Agenda
The programme for RWE 2022 is currently being prepared and will be announced soon. To get a flavour of a RWE LIVE event, you can see the original draft programme planned for RWE 2020 below – please note that the programme will be fully updated for 2022, so timings and formats may change.
| DAY ONE – Wednesday 1 April 2020 | |||
|
08:15 |
09:00 |
Registration, breakfast, coffee and exhibition | |
|
09:00 |
09:05 |
Welcome address
Laura Dormer, Editorial Director, Future Science Group |
|
|
09:05 |
09:20 |
Opening remarks
Conference Chair: Charles Makin, Global Head Real-World Evidence Strategy, Biogen |
|
|
09:20 |
09:50 |
Opening keynote conversation
Understanding the human angle – the impact of rare diseases: my family’s story Jean-Christophe Novelli |
|
|
09:50 |
11:05 |
Panel conversation: co-ordination and collaboration: rare diseases across Europe
Speakers: Alastair Kent, Independent Joanne Hackett, CCO, Genomics England Eric Low, Eric Low Consulting |
|
|
11:05 |
11:35 |
Morning coffee and exhibition | |
|
|
|
LISTEN & LEARN ZONE |
CONVERSATION & COLLABORATION ZONE |
|
Regulatory tools and pathways |
|||
|
11:35 |
12:05 |
Handling real-world evidence to support conditional access to treatments: the NICE experience
Speaker: Brad Groves, Associate Director, Managed Access, The National Institute for Health and Care Excellence (NICE) |
Roundtable conversations – a choice of concurrent conversations, designed to enable collaboration |
|
12:05 |
12:35 |
Why real-world evidence matters to payers: managing uncertainty and facilitating novel payment models
Speaker: Lotte Steuten, Vice President & Head of Consulting, Office of Health Economics |
|
|
12:35 |
13:05 |
Responding to regulatory requests with data generation
Speaker: Chris Knight, Senior Director, Health Economics, RTI Health Solutions |
|
|
13:05 |
14:10 |
Lunch and exhibition | |
|
|
|
LISTEN & LEARN ZONE |
CONVERSATION & COLLABORATION ZONE |
|
Understanding reimbursement |
|||
|
14:10 |
14:30 |
Handling real-world evidence to support reimbursement
|
Roundtable conversations – a choice of concurrent conversations, designed to enable collaboration |
|
14:30 |
15:00 |
Gaining clarity on real-world evidence and payer models across Europe
Speaker: Paolo Morgese, EU Director of Market Access and Member Relations, Alliance for Regenerative Medicine |
|
|
15:00 |
15:40 |
Afternoon tea and exhibition | |
|
15:40 |
16:10 |
Post-launch data collection for the purpose of ATMP reimbursement
Speaker: Panos Kefalas, Head of Health Economics and Market Access, Cell and Gene Therapy Catapult |
Roundtable conversations – a choice of concurrent conversations, designed to enable collaboration |
|
16:10 |
16:40 |
Policy and cost–effectiveness in rare diseases: how should we assess value?
Speaker: Christian Hill, CEO, MAP BioPharma |
|
|
16:40 |
16:55 |
Closing questions | |
|
17:00 |
18:30 |
Drinks reception | |
| DAY TWO – Thursday 2 April 2020 | |||
|
08:15 |
09:00 |
Registration, breakfast, coffee and exhibition | |
|
09:00 |
09:20 |
Welcome address
Laura Dormer, Editorial Director, Future Science Group |
|
|
09:20 |
09:50 |
Big data, genomics and trust – making the UK the centre for health data science | |
|
09:50 |
10:35 |
Panel conversation: regulation and access to treatments for rare diseases: an industry perspective
Speaker: Leslie Galloway, Chairman, Ethical Medicines Industry Group |
|
|
10:35 |
11:05 |
Morning coffee and exhibition | |
|
|
|
LISTEN & LEARN ZONE |
CONVERSATION & COLLABORATION ZONE |
|
Patients and transparency |
|||
|
11:05 |
11:35 |
Effective strategies for locating patients using real-world evidence
Speaker: Maya Zlatanova, Co-Founder & CEO, FindMeCure |
Roundtable conversations – a choice of concurrent conversations, designed to enable collaboration |
|
11:35 |
12:05 |
Achieving transparency in the generation and use of real-world evidence
Speaker: Richard White, Chief Operating Officer, Oxford PharmaGenesis Ltd. |
|
|
12:05 |
12:35 |
The use of RWE across the medicine lifecycle: benefits, challenges and solutions
Speaker: Amanda Cole, Principal Economist, Office of Health Economics |
|
|
12:35 |
13:05 |
Transforming health care through healthcare data | |
|
13:05 |
14:10 |
Lunch and exhibition | |
|
|
|
LISTEN & LEARN ZONE | CONVERSATION & COLLABORATION ZONE |
| Session title TBA |
|||
|
14:10 |
14:40 |
Collaboration and transparency: creating a platform for developing data sharing across Europe for orphan drugs
Speaker: Karen Facey, Senior Research Fellow, IMPACT HTA, Co-Lead Investigator, WP10 Appraisal of Orphan Medicinal Products |
Roundtable conversations – a choice of concurrent conversations, designed to enable collaboration |
|
14:40 |
15:10 |
Next-generation health technology assessment: supporting patient-centred, real-time decision making
Speaker: Dalia Dawoud, Scientific Adviser, Science, Policy and Research Programme, NICE |
|
|
15:10 |
15:40 |
Afternoon tea and exhibition | |
|
15:40 |
16:10 |
Drug repurposing for rare diseases
Speaker: Rick Thompson, CEO, Findacure |
Roundtable conversations – a choice of concurrent conversations, designed to enable collaboration |
|
16:10 |
16:30 |
Fireside chat: topic TBA
Charles Makin, Global Head Real-World Evidence Strategy, Biogen |
|
|
16:30 |
17:00 |
Closing keynote: Next steps in real-world evidence and rare diseases
Speaker: Charles Makin, Global Head Real-World Evidence Strategy, Biogen |
|